numares announces FDA 510(k) Submission of AXINON System®, a NMR platform for metabolomics-based, AI-driven Diagnostics
24.3.2021 14:00:00 EET | Business Wire | Press release
Leading NMR diagnostics company numares AG today announced that the company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AXINON® IVD System, a NMR-platform for AI-driven, metabolomics-based diagnostics. If cleared, AXINON® would become the first NMR-based clinical laboratory system using AI-evaluated metabolic data. Several multi-marker assays for AXINON® will cover numerous unmet medical needs, in order to prevent, diagnose and treat disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005057/en/
numares AXINON® IVD System: The AI-driven AXINON® Software, in combination with advanced NMR technology, refined by numares' proprietary Magnetic Group SignalingTM, allows metabolomics-based precision diagnostics by implementation of various numares' tests, e.g. to identify early kidney rejection in post-transplant surveillance, assess kidney function by improved determination of glomerular filtration rate (GFR) and risk for cardiovascular disease (CVD). (Photo: Business Wire)
The clearance of AXINON® would bring a novel diagnostic approach to clinical laboratories, the combination of several metabolic biomarkers, so-called metabolite constellations, analyzed by advanced nuclear magnetic resonance (NMR) technology and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software.
"This U.S. regulatory filing for its diagnostics platform is an important milestone for numares," said Winton Gibbons, President - US and co-Chief Executive Officer of numares. “After entering into collaborations on joint diagnostics development with analytical instrumentation and solution provider Bruker Corporation in January 2021, and with Mayo Clinic Laboratories in 2019, this FDA submission is the first step in our common endeavor to bring NMR diagnostics into routine clinical use, and make metabolomics-based diagnostics accessible to the patients.”
numares is currently developing multi-marker algorithms for several diagnostic tests on the AXINON® IVD System. These include AXINON® GFRNMR to reliably assess kidney function by improved determination of glomerular filtration rate (GFR). numares expects to submit this test to the FDA also in the first half 2021. The third assay AXINON® renalTX-SCORE® is intended to reliably identify early kidney rejection in post-transplant surveillance, and be submitted to the FDA in 2022. Further multi-marker tests are in development, e.g., for liver disease, cancer detection, and multiple sclerosis.
Dr. Maulik Shah, numares’ Medical Director comments: “AXINON® provides clinical laboratories with a powerful technology that leverages the information-rich metabolome with artificial intelligence to give healthcare professionals new insights into disease diagnosis and management for improved patient outcomes. At the same time, automation capabilities, excellent precision, easy operability will allow easy adaption of the FDA-cleared system by clinical laboratories and will make AXINON® an indispensable routine diagnostic tool in precision medicine.”
“The 510(k) submission of our AXINON® System is an important step and prerequisite to further strengthen commercialization of numares’ products in the United States”, concludes Dr. Volker Pfahlert, co-CEO of numares and chairman of the executive board. “Metabolic disorders are a rapidly increasing problem and major challenge to today’s healthcare systems. Patients will benefit from our approach to consider the patient's metabolome with sophisticated algorithms. Once cleared by the FDA, we believe AXINON® has the potential to meaningfully improve health outcomes and quality of life for millions of patients.”
The AXINON® System consists of AI-based AXINON® Software, ready-to-use AXINON® kits, and an advanced NMR technology, refined by numares’ proprietary Magnetic Group SignalingTM to ensure highly standardized and automated processing of serum or urine samples in high-throughput.
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005057/en/
Contact information
numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail:
christiane.proll@numares.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blind Sailor Mitsuhiro Iwamoto Redefines the Limits of Possibility Through Technology in a Historic Trans-Pacific Project3.2.2026 05:00:00 EET | Press release
Mitsuhiro Iwamoto, a Japanese sailor based in San Diego, who is taking on the world’s first solo, non-stop trans-Pacific crossing by a blind sailor as part of the Blind Sailor Single-Handed Pacific Crossing Project 2027, held a press conference on January 28 (local time) in San Diego, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128531637/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific Project URL: https://hiros-choice.com/ On January 22 (local time), Iwamoto delivered a speech at the World Economic Forum Annual Meeting 2026 (WEF) under the theme “Sailing Through Barriers.” Speaking about the upcoming voyage, he said, “Boundaries are not decided by others. They are transcended by choice.” WEF URL: https://www.weforum.org/meetings/world-economic-forum-annual-meeting-2026/sessions/sailing-through-barriers/ During the press conference, he explained that all navigational infor
TestMu AI (Formerly LambdaTest) Recognized in Independent Research on Autonomous Testing Platforms, Q4 20252.2.2026 19:24:00 EET | Press release
TestMu AI (formerly known as LambdaTest), the world’s first full-stack Agentic Quality Engineering platform, today announced its inclusion in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025, an independent research report evaluating vendors in the autonomous testing market. The report identifies TestMu AI as a cloud-based platform for unified test orchestration and execution. It notes the platform's capabilities in cross-browser testing, real device cloud, and AI-driven automation. Specifically, the research cites TestMu AI’s testing of AI systems across dimensions, providing metrics for accuracy, intent recognition, and hallucination detection with configurable thresholds. Additionally, the report recognizes TestMu AI’s AI-powered test data generation, citing its support for Large Language Models (LLMs), multimodal inputs, and compliance-aligned workflows. The report also noted the company's strong community strategy and customers praise its responsive customer support, whi
Current Chemicals Launches as Independent Specialty Materials Manufacturer, Building on 75-Year GE Legacy with Backing from Momentum Global Ventures2.2.2026 18:04:00 EET | Press release
Today marks the debut of Current Chemicals, Inc. (CCI) as a fully independent U.S.-based specialty materials manufacturer. Backed by strategic investor Momentum Global Ventures, CCI is charting a bold new path as a trusted partner for materials innovation, custom chemistry, and U.S.-based downstream manufacturing of rare earths and critical materials. The partnership between U.S.-based CCI and Netherlands-based Momentum Global Ventures reflects a strengthening transatlantic alliance at a pivotal moment for global supply chains. This partnership underscores a shared commitment to secure, reliable, and innovation-driven materials infrastructure. Originally the chemical division of GE Lighting, the team behind CCI has served as the quiet force behind groundbreaking technologies for more than 75 years, developing processes and manufacturing advanced materials for displays, lighting, energy storage, and more. As an independent company, CCI is poised to expand its impact across industries de
Laserfiche’s Taylor Grosso Honored as 2026 CRN® Channel Chief2.2.2026 17:00:00 EET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — announced today that CRN® — a brand of The Channel Company — has selected Taylor Grosso, senior director, channel, Americas, as a 2026 CRN® Channel Chief. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. Grosso oversees Laserfiche’s Americas channel sales team, including the U.S., Canada, and Latin America, focusing on empowering Laserfiche Solution Providers to stay competitive as the market evolves. As more organizations seek out AI-powered tools to enhance productivity, Grosso prepares partners with the resources they need to quickly learn and sell Laserfiche’s industry-leading AI-powered document management solutions. By working closely with partners on building targeted business plans, Grosso and his team enable faster customer adoption of AI while driving revenue growth. “Over the past year,
Conga Completes Acquisition of PROS B2B Business2.2.2026 16:55:00 EET | Press release
Conga, a leader for AI-powered innovation in configure, price, quote (CPQ), contract lifecycle management (CLM), and document automation, today announced it has completed the acquisition of the B2B business of PROS Holdings, Inc (“PROS”) from certain investment funds affiliated with Thoma Bravo, the world’s largest software-focused investment firm. This transaction unites two industry leaders to help enterprises maximize revenue, reduce risk, and improve profitability. By bringing together AI-driven pricing optimization, configuration, quoting, and contracting capabilities, the combined company creates a differentiated enterprise platform that connects the commerce chain and enables end-to-end revenue orchestration from price to signature. The expanded Conga leadership team will continue to be led by CEO Dave Osborne. “To operate as connected, intelligent businesses, enterprises need a commerce chain that keeps everyone moving in the same direction,” said Osborne. “By bringing Conga an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom